NEW YORK (GenomeWeb News) – Fluxion Biosciences today said that it has signed a reagent supply and collaboration agreement with Rubicon Genomics aimed at circulating tumor cell applications.

The South San Francisco, Calif.-based firm said that the alliance will integrate enrichment methods for rare cells using Fluxion's IsoFlux System with Rubicon's NovaPlex sample preparation kits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.